MX2021003653A - Inositol fosfatos para el tratamiento de calcificacion ectopica. - Google Patents

Inositol fosfatos para el tratamiento de calcificacion ectopica.

Info

Publication number
MX2021003653A
MX2021003653A MX2021003653A MX2021003653A MX2021003653A MX 2021003653 A MX2021003653 A MX 2021003653A MX 2021003653 A MX2021003653 A MX 2021003653A MX 2021003653 A MX2021003653 A MX 2021003653A MX 2021003653 A MX2021003653 A MX 2021003653A
Authority
MX
Mexico
Prior art keywords
treatment
calcifications
inositol
inositol phosphate
inositol phosphates
Prior art date
Application number
MX2021003653A
Other languages
English (en)
Inventor
Bestard Joan Perelló
Roca Carolina Salcedo
Hamann Ana- Zeralda Canals
Original Assignee
Sanifit Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics S A filed Critical Sanifit Therapeutics S A
Publication of MX2021003653A publication Critical patent/MX2021003653A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se relaciona con composiciones, métodos, dosis, pautas posológicas, artículos de fabricación y kits para el tratamiento y/o la prevención de calcificaciones ectópicas y, en particular, calcificaciones cutáneas tales como calcificaciones debidas a calcifilaxia que comprenden inositol fosfato, análogos de inositol fosfato, derivados de inositol fosfato o combinaciones de estos. En un aspecto particular, la divulgación proporciona una pauta posológica para tratar la calcifilaxia que comprende la administración de 6 mg/kg a 9 mg/kg de dosis diarias de mio-inositol hexafosfato, tres veces por semana, durante al menos 1 a 8 meses.
MX2021003653A 2018-10-11 2018-10-11 Inositol fosfatos para el tratamiento de calcificacion ectopica. MX2021003653A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201830988A ES2754280A1 (es) 2018-10-11 2018-10-11 Pautas posológicas de IP y análogos de IP para el tratamiento de calcificaciones ectópicas
PCT/IB2018/057904 WO2020074944A1 (en) 2018-10-11 2018-10-11 Inositol phosphates for the treatment of ectopic calcification

Publications (1)

Publication Number Publication Date
MX2021003653A true MX2021003653A (es) 2021-06-23

Family

ID=64109944

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021003653A MX2021003653A (es) 2018-10-11 2018-10-11 Inositol fosfatos para el tratamiento de calcificacion ectopica.
MX2024005721A MX2024005721A (es) 2018-10-11 2021-03-26 Inositol fosfatos para el tratamiento de calcificacion ectopica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024005721A MX2024005721A (es) 2018-10-11 2021-03-26 Inositol fosfatos para el tratamiento de calcificacion ectopica.

Country Status (9)

Country Link
US (2) US10973838B2 (es)
KR (3) KR102651652B1 (es)
CN (1) CN112839661A (es)
AU (1) AU2018445164A1 (es)
BR (1) BR112021006004A2 (es)
CA (1) CA3113377A1 (es)
ES (1) ES2754280A1 (es)
MX (2) MX2021003653A (es)
WO (1) WO2020074944A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839661A (zh) * 2018-10-11 2021-05-25 萨尼菲特治疗有限公司 用于治疗异位钙化的肌醇磷酸酯类
WO2024023359A1 (en) * 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL132418C (es) 1962-04-13
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US5330979A (en) 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US4826675A (en) 1988-02-17 1989-05-02 Colgate-Palmolive Company Anticalculus oral composition
JPH01294631A (ja) 1988-05-19 1989-11-28 Sanwa Kagaku Kenkyusho Co Ltd 糖尿性疾患治療予防剤及び飲食、し好物
US5041429A (en) 1988-06-01 1991-08-20 Sanwa Kagaku Kenkyusho Co., Ltd. Cell activators, circulatory ameliorators and edible compositions
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5206226A (en) 1990-10-24 1993-04-27 Robert Sabin Method of treatment of Parkinsons's disease using phytic acid
US5112814A (en) 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
DE29910454U1 (de) 1999-06-10 1999-09-23 Vitasyn GmbH, 10789 Berlin Mittel zur Therapie von Hyperphosphatämie
EP1242057A2 (en) 1999-11-02 2002-09-25 DepoMed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
CA2396782A1 (en) 2000-02-04 2001-08-09 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
WO2002010177A1 (en) 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
EP1438027A1 (en) 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2004287440A1 (en) 2003-10-28 2005-05-19 Emory University Dialysates and methods and systems related thereto
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
US20070212449A1 (en) 2006-03-02 2007-09-13 Shamsuddin Abulkalam M Reduction of the titratable acidity and the prevention of tooth and other bone degeneration
BRPI0708725A2 (pt) 2006-03-09 2011-06-07 Waratah Pharmaceuticals Inc formulação de poliálcool de ciclohexano para o tratamento de doenças de agregação de proteìna
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US20110091440A1 (en) 2009-03-27 2011-04-21 Robert Sabin Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases
EA025137B1 (ru) 2009-04-06 2016-11-30 Кририн Лтд. Раствор для диализа, включающий одно или более соединений креатина и способ его получения
US20110293595A1 (en) 2010-03-26 2011-12-01 Robert Sabin Prophylactic and therapeutic treatment of Alzheimer's Disease, neuro-degenerative diseases, protein aggregation diseases, Parkinson's Disease and amyloid diseases, using phytic acid and phytate
US8277909B2 (en) 2010-10-22 2012-10-02 Carestream Health, Inc. Transparent ink-jet recording films, compositions, and methods
CN105949234B (zh) 2011-09-29 2018-07-10 苏黎世联邦理工学院 用于治疗艰难梭菌感染的药物化合物
US9751903B2 (en) * 2011-09-29 2017-09-05 Eth Zurich Pharmaceutical compounds for use in the therapy of clostridium difficile infection
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
WO2013167741A1 (fr) 2012-05-10 2013-11-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Thiosulfate de sodium pour le traitement des calcifications ectopiques
US20130302448A1 (en) 2012-05-10 2013-11-14 Guy Parc Phytin aqueous solution and use of said solution for the preparation of a liquid nutritional supplement or a cosmetic composition
US9364490B2 (en) 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
EP3848053A1 (en) * 2015-12-11 2021-07-14 Universität Bern Inositol derivatives for use in pathological crystallization
AU2016366503B2 (en) 2015-12-11 2021-02-04 ETH Zürich 4,6-di-(O-thiophosphate)-inositol-1,2,3,5-tetra-O-sulfate for C. difficile infection
ITUB20160180A1 (it) 2016-01-27 2017-07-27 Lo Li Pharma Srl Somministrazione topica/locale di inositolo esafosfato come coadiuvante nei trattamenti antitumorali
TWI730039B (zh) 2016-01-29 2021-06-11 日商富士藥品股份有限公司 新穎雙膦酸化合物
CA3014457A1 (en) 2016-02-24 2017-08-31 Innovative Surface Technologies, Inc. Crystallization inhibitor compositions for implantable urological devices
WO2017192200A1 (en) 2016-05-05 2017-11-09 The Research Foundation For The State Unversity Of New York Compositions for treating periodontitis and dental calculus accumulation
CN112839661A (zh) * 2018-10-11 2021-05-25 萨尼菲特治疗有限公司 用于治疗异位钙化的肌醇磷酸酯类
EP3818983A1 (en) * 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification

Also Published As

Publication number Publication date
AU2018445164A1 (en) 2021-04-22
ES2754280A1 (es) 2020-04-16
KR102683836B1 (ko) 2024-07-09
KR20210076904A (ko) 2021-06-24
KR20240110085A (ko) 2024-07-12
US20210290642A1 (en) 2021-09-23
BR112021006004A2 (pt) 2021-06-29
KR102651652B1 (ko) 2024-03-26
US12070469B2 (en) 2024-08-27
CA3113377A1 (en) 2020-04-16
KR20240042554A (ko) 2024-04-02
US20200179422A1 (en) 2020-06-11
WO2020074944A1 (en) 2020-04-16
MX2024005721A (es) 2024-05-27
CN112839661A (zh) 2021-05-25
US10973838B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
MX2024005721A (es) Inositol fosfatos para el tratamiento de calcificacion ectopica.
NZ751418A (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
NZ722326A (en) Tricyclic compounds as anticancer agents
MX2019003363A (es) Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
MX2022004971A (es) Compuestos de fosfato de inositol para su uso en el tratamiento, la inhibicion de la evolucion o la prevencion de la calcificacion cardiovascular.
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
MX2019006843A (es) Inhibidor de cdk4/6.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2019005104A (es) Composiciones de zinc-y-pga y métodos para tratar el cancer.
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
TWI332007B (en) Use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2015004760A (es) Fosfestrol para uso en el tratamiento curativo o paliativo de cancer de prostata.